Drug Type Fusion protein |
Synonyms Efmarodocokin alfa + [5] |
Target |
Mechanism IL-22R modulators(Interleukin-22 receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Start Date19 Nov 2020 |
Sponsor / Collaborator |
Start Date02 Jun 2020 |
Sponsor / Collaborator Genentech, Inc. [+1] |
Start Date01 Jun 2019 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 3 | US | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 3 | IE | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 3 | IT | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 3 | ES | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 3 | GE | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 2 | GE | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 2 | ES | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 2 | IE | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 2 | IT | 26 Oct 2018 | |
Colitis, Ulcerative | Phase 2 | US | 26 Oct 2018 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 143 | wmhonxoeds(rsgvreyugk) = jepfuajukn umbuwiukzi (aduuosvxdd, kuqqpsllju - cdgtbliqke) View more | - | 29 Sep 2023 | |||
Phase 2 | 396 | (ejuvxibzot) = rnkvexjtmm fntbiodaab (vgnamzwqkr ) | Negative | 01 Jan 2023 | |||
(ejuvxibzot) = qzmitfngyo fntbiodaab (vgnamzwqkr ) |